Preparation modification strategies for clinical treatment drugs of Parkinson's disease

VernacularTitle:帕金森病临床治疗药物的制剂改良策略
Author: Meng-jiao HE ¹ ; Yi-fang XIAO ¹ ; Xiang-an-ni KONG ¹ ; Zhi-hao LIU ¹ ; Xiao-guang WANG ² ; Hao FENG ² ; Jia-sheng TU ¹ ; Qian CHEN ¹ ; Chun-meng SUN ¹
Author Information

1. NMPA Key Laboratory for Research and Evaluation of Pharmaceutical Preparations and Excipients, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China
2. Nanjing Lanming Biomedical Technology Co., Ltd., Nanjing 210028, China
Publication Type:Research Article
Keywords: Parkinson's disease; levodopa; carbidopa; opamine agonist; osage form
From: Acta Pharmaceutica Sinica 2024;59(3):574-580
CountryChina
Language:Chinese
Abstract: Parkinson's disease (PD) is a chronic neurodegenerative disease. At present, levodopa and other drugs are mainly used for dopamine supplementation therapy. However, the absorption of levodopa in the gastrointestinal tract is unstable and its half-life is short, and long-term use of levodopa will lead to the end-of-dose deterioration, dyskinesia, the "ON-OFF" phenomenon and other symptoms. Therefore, new preparations need to be developed to improve drug efficacy, reduce side effects or improve compliance of patients. Based on the above clinical needs, this review briefly introduced the preparation modification strategies for the treatment of PD through case analysis, in order to provide references for the research and development of related preparations.